Treatment and outcomes of invasive fusariosis: Review of 65 cases from the PATH Alliance® registry

Mycoses

Volumn 57, Issue 11, 2014, Pages 652-658

  Horn, David L ^a   Freifeld, Alison G ^b   Schuster, Mindy G ^c   Azie, Nkechi E ^d   Franks, Billy ^d   Kauffman, Carol A ^e  

^a David Horn LLC   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Epidemiology; Fusarium; Invasive mould infection; PATH Alliance

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; CORTICOSTEROID; ECHINOCANDIN; FLUCONAZOLE; GALACTOMANNAN; POSACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT; TRIAZOLE DERIVATIVE;

ADULT; ANTIMICROBIAL THERAPY; ARTICLE; CANADA; CONTROLLED STUDY; CROSS REACTION; DESCRIPTIVE RESEARCH; FATALITY; FEMALE; FUSARIOSIS; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; INVASIVE FUSARIOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; NEUTROPENIA; PATIENT IDENTIFICATION; PRIORITY JOURNAL; REGISTER; SURVIVAL RATE; SYSTEMIC MYCOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES; AGED; DRUG EFFECTS; FUSARIUM; MICROBIOLOGY; MORTALITY; PHYSIOLOGY; PROSPECTIVE STUDY; SURVIVAL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANADA; FEMALE; FUSARIOSIS; FUSARIUM; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGISTRIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TRIAZOLES; UNITED STATES; VORICONAZOLE; YOUNG ADULT;

EID: 84907957757     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12212     Document Type: Article

References (20)

1. Dignani MC, Anaissie E. Human fusariosis. Clin Microbiol Infect 2004; 10(Suppl. 1): 67-75.
2. Bourgeois GP, Cafardi JA, Sellheyer K, Andea AA. Disseminated Fusarium infection originating from paronychia in a neutropenic patient: a case report and review of the literature. Cutis 2010; 85: 191-4.
3. Carneiro HA, Coleman JJ, Restrepo A, Mylonakis E. Fusarium infection in lung transplant patients: report of 6 cases and review of the literature. Medicine (Baltimore) 2011; 90: 69-80.
4. Hu S, Fan VC, Koonapareddy C, Du TT, Asbell PA. Contact lens-related Fusarium infection: case series experience in New York City and review of fungal keratitis. Eye Contact Lens 2007; 33: 322-8.
5. Liu JY, Chen WT, Ko BS et al. Combination antifungal therapy for disseminated fusariosis in immunocompromised patients: a case report and literature review. Med Mycol 2011; 49: 872-8.
6. Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 2007; 20: 695-704.
7. Torres HA, Raad II, Kontoyiannis DP. Infections caused by Fusarium species. J Chemother 2003; 15(Suppl. 2): 28-35.
8. Muhammed M, Coleman JJ, Carneiro HA, Mylonakis E. The challenge of managing fusariosis. Virulence 2011; 2: 91-96.
9. Nucci M, Marr KA, Vehreschild MJ et al. Improvement in the outcome of invasive fusariosis in the last decade. Clin Microbiol Infect 2013. [Epub ahead of print].
10. Ho DY, Lee JD, Rosso F, Montoya JG. Treating disseminated fusariosis: amphotericin B, voriconazole or both? Mycoses 2007; 50: 227-31.
11. Lortholary O, Obenga G, Biswas P et al. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother 2010; 54: 4446-50.
12. Nucci M, Marr KA, Queiroz-Telles F et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis 2004; 38: 1237-42.
13. Raad II, Hachem RY, Herbrecht R et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006; 42: 1398-403.
14. Muhammed M, Anagnostou T, Desalermos A et al. Fusarium infection: report of 26 cases and review of 97 cases from the literature. Medicine (Baltimore) 2013; 92: 305-16.
15. ® registry and invasive fungal infections: update 2012. Diagn Microbiol Infect Dis 2012; 73: 293-300.
16. Horn DL, Fishman JA, Steinbach WJ et al. Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections. Diagn Microbiol Infect Dis 2007; 59: 407-14.
17. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
18. Tortorano AM, Esposto MC, Prigitano A et al. Cross-reactivity of Fusarium spp. in the Aspergillus Galactomannan enzyme-linked immunosorbent assay. J Clin Microbiol 2012; 50: 1051-3.
19. Nucci M, Carlesse F, Cappellano P et al. Earlier diagnosis of invasive fusariosis with Aspergillus serum galactomannan testing. PLoS ONE 2014; 9: e87784.
20. Nucci M, Anaissie EJ, Queiroz-Telles F et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer 2003; 98: 315-9.